BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 26807640)

  • 1. The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
    Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Hanaoka T; Hasegawa K; Fujiwara K
    Int J Gynecol Cancer; 2016 Mar; 26(3):443-8. PubMed ID: 26807640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).
    Fujiwara H; Ushijima K; Nagao S; Takei Y; Shimada M; Takano M; Yoshino K; Kawano Y; Hirashima Y; Nagase S; Nishio S; Nishikawa T; Ito K; Shoji T; Kimura E; Takano T; Sugiyama T; Kigawa J; Fujiwara K; Suzuki M
    Int J Clin Oncol; 2019 Oct; 24(10):1284-1291. PubMed ID: 31127479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
    Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
    Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
    Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ
    Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
    Vandenput I; Vergote I; Neven P; Amant F
    Int J Gynecol Cancer; 2012 May; 22(4):617-22. PubMed ID: 22426408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
    Pitakkarnkul S; Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Pataradool K; Prutthiphongsit W; Khunnarong J; Thavaramara T
    Asian Pac J Cancer Prev; 2013; 14(4):2421-7. PubMed ID: 23725151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
    Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
    Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
    Tas F; Guney N; Derin D; Aydiner A; Topuz E
    Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103).
    Lindemann K; Beale PJ; Rossi E; Goh JC; Vaughan MM; Tenney ME; Martyn JK; Sommeijer D; Iglesias JL; Kremmidiotis G; Simpson J; Doolin E; Lavranos TC; Leske A; Veillard AS; Espinoza D; Stockler MR; Rischin D;
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):97-105. PubMed ID: 30368585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
    Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
    Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
    Sufliarsky J; Chovanec J; Svetlovska D; Minarik T; Packan T; Kroslakova D; Lalabova R; Helpianska L; Horvathova D; Sevcik L; Spacek J; Laluha A; Tkacova V; Malec V; Rakicka G; Magdin D; Jancokova I; Dorr A; Stresko M; Habetinek V; Koza I
    Neoplasma; 2009; 56(4):291-7. PubMed ID: 19473054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.
    Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Sykiotis C; Papachristodoulou A; Tountas N; Panayiotides J; Economopoulos T
    Gynecol Oncol; 2008 Sep; 110(3):299-303. PubMed ID: 18602677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
    Bruchim I; Weeg N; Alpert Y; Sade D; Piura E; Fishman A
    Int J Gynecol Cancer; 2016 May; 26(4):640-7. PubMed ID: 27101523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of chemotherapy according to
    Brouillard-Saby F; Saint-Martin C; Ray-Coquard I; Gladieff L; Pomel C; Colombo PE; Classe JM; Chevrier M; Joly F; De la Motte Rouge T; Floquet A; Sabatier R; Barranger E; Costaz H; Leblanc E; Marchal F; Pautier P; Bosquet L; Rodrigues M
    Int J Gynecol Cancer; 2023 Apr; 33(4):577-584. PubMed ID: 36631150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
    Volgger B; Zeimet AG; Reinthaller A; Petru E; Schauer C; Klein M; Sevelda-Schwarzgruber U; Bogner G; Wolfram G; Marth C
    Int J Gynecol Cancer; 2015 Feb; 25(2):257-62. PubMed ID: 25611899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
    Del Carmen MG; Supko JG; Horick NK; Rauh-Hain JA; Clark RM; Campos SM; Krasner CN; Atkinson T; Birrer MJ
    Cancer; 2016 Nov; 122(21):3297-3306. PubMed ID: 27421044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
    Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
    Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
    Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
    Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
    Ang JE; Shah RN; Everard M; Keyzor C; Coombes I; Jenkins A; Thomas K; A'Hern R; Jones RL; Blake P; Gabra H; Hall G; Gore ME; Kaye SB
    Ann Oncol; 2009 Nov; 20(11):1787-93. PubMed ID: 19542250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.